Cargando…

P-039: ALTERNATIVE DOSING AND PREVENTION OF TRANSFUSIONS (ADAPT): A PROSPECTIVE TRIAL EVALUATING TRANSFUSION UTILIZATION AND THE FEASIBILITY OF PHARMACOKINETIC HYDROXYUREA DOSING IN CHILDREN WITH SICKLE CELL ANEMIA IN UGANDA

Detalles Bibliográficos
Autores principales:	POWER-HAYS, A., R., NAMAZZI, C., KATO, A., CONROY, H., HUME, C., JOHN, S., STUBER, MA, A., LANE, T., LATHAM, R., OPOKA, R., WARE
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Poster Presentations
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429761/ http://dx.doi.org/10.1097/01.HS9.0000873052.78363.19

Ejemplares similares

O-01: HYDROXYUREA REDUCES THE TRANSFUSION BURDEN IN CHILDREN WITH SICKLE CELL ANEMIA IN SUB-SAHARAN AFRICA: THE REACH EXPERIENCE
por: A., POWER-HAYS, et al.
Publicado: (2022)

Cost-Effectiveness of Hydroxyurea for Sickle Cell Anemia in a Low-Income African Setting: A Model-Based Evaluation of Two Dosing Regimens
por: Teigen, David, et al.
Publicado: (2023)

PI-08: HIGH DISEASE BURDEN, MORBIDITY AND MORTALITY AMONG CHILDREN WITH SICKLE CELL ANAEMIA IN UGANDA
por: R., NAMAZZI, et al.
Publicado: (2022)

Intensive hydroxyurea dosing in very young children with sickle cell anemia
por: Wang, Winfred C., et al.
Publicado: (2023)

Zinc for Infection Prevention in Sickle Cell Anemia (ZIPS): study protocol for a randomized placebo-controlled trial in Ugandan children with sickle cell anemia
por: Datta, Dibyadyuti, et al.
Publicado: (2019)

Hydroxyurea pharmacokinetics and precision dosing in low-resource settings
por: Smart, Luke R., et al.
Publicado: (2023)

O-12: BUILDING LOCAL CAPACITY FOR HYDROXYUREA PHARMACOKINETICS AND PRECISION DOSING IN LOW-RESOURCE SETTINGS
por: L., SMART, et al.
Publicado: (2022)

Blood Transfusion Vs. Hydroxyurea for Stroke Prevention in Children With Sickle Cell Anemia: A Systematic Review and Meta-Analysis
por: Hafiz, Tamara A, et al.
Publicado: (2022)

Combination dose-escalated hydroxyurea and transfusion: an approach to conserve blood during the COVID-19 pandemic
por: Nickel, Robert Sheppard, et al.
Publicado: (2020)

Hydroxyurea Therapy for Children With Sickle Cell Anemia in Sub‐Saharan Africa: Rationale and Design of the REACH Trial
por: McGann, Patrick T., et al.
Publicado: (2015)

TCD With Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, randomised controlled trial
por: Ware, Russell E., et al.
Publicado: (2015)

Metabolic signatures of cardiorenal dysfunction in plasma from sickle cell patients as a function of therapeutic transfusion and hydroxyurea treatment
por: D’Alessandro, Angelo, et al.
Publicado: (2023)

Hydroxyurea Treatment in Transfusion-Dependent β-Thalassemia Patients
por: Bordbar, Mohammad Reza, et al.
Publicado: (2014)

Hydroxyurea and blood transfusion therapy for Sickle cell disease in South Asia: inconsistent treatment of a neglected disease
por: Darshana, Thamal, et al.
Publicado: (2021)

Hydroxyurea and sickle cell anemia: effect on quality of life
por: Ballas, Samir K, et al.
Publicado: (2006)

Stroke Avoidance for Children in REpública Dominicana (SACRED): Protocol for a Prospective Study of Stroke Risk and Hydroxyurea Treatment in Sickle Cell Anemia
por: Jeste, Neelum D, et al.
Publicado: (2017)

Decreased parasite burden and altered host response in children with sickle cell anemia and severe anemia with malaria
por: Henrici, Ryan C., et al.
Publicado: (2021)

Impact of a National Lockdown for COVID-19 on Morbidity and Mortality Among Children with Sickle Cell Anaemia at a Tertiary Care Hospital in Uganda
por: Namazzi, Ruth, et al.
Publicado: (2020)

EXpanding Treatment for Existing Neurological Disease (EXTEND): An Open-Label Phase II Clinical Trial of Hydroxyurea Treatment in Sickle Cell Anemia
por: Rankine-Mullings, Angela E, et al.
Publicado: (2016)

Population pharmacokinetics and pharmacodynamics of hydroxyurea in sickle cell anemia patients, a basis for optimizing the dosing regimen
por: Paule, Ines, et al.
Publicado: (2011)

Effectiveness of Pharmacokinetic-Guided Hydroxyurea Dose Individualization in Patients with Sickle Cell Anemia: A Mini-Review
por: dos Santos Neres, Joelma Santana, et al.
Publicado: (2023)

Transfusion service knowledge and immunohaematological practices related to sickle cell disease and thalassemia
por: Fasano, R. M., et al.
Publicado: (2019)

P-047: PROSPECTIVE IDENTIFICATION OF VARIABLES AS OUTCOMES FOR TREATMENT (PIVOT): A PHASE II CLINICAL TRIAL OF HYDROXYUREA FOR CHILDREN AND ADULTS WITH HBSC DISEASE
por: L., SMART, et al.
Publicado: (2022)

Neurological Complications following Blood Transfusions in Sickle Cell Anemia
por: Alharbi, Hana, et al.
Publicado: (2017)

SUN-039 Estradiol Dose and Concentrations in Transfeminine Individuals
por: Nolan, Brendan J, et al.
Publicado: (2020)

Effects of hydroxyurea on cytotoxicity, inflammation and oxidative stress markers in neutrophils of patients with sickle cell anemia: dose-effect relationship
por: Pedrosa, Alano Martins, et al.
Publicado: (2021)

The Effects of Treatment with Blood Transfusion, Iron Chelation and Hydroxyurea on Puberty, Growth and Spermatogenesis in Sickle Cell Disease (SCD): A short update
por: Soliman, Ashraf T, et al.
Publicado: (2021)

Examination of Reticulocytosis among Chronically Transfused Children with Sickle Cell Anemia
por: Kaushal, Megha, et al.
Publicado: (2016)

O-07: TRANSFUSION PRACTICE, POST-TRANSFUSION COMPLICATIONS AND RISK FACTORS IN SICKLE CELL DISEASE IN SENEGAL
por: M., SECK, et al.
Publicado: (2022)

Novel Use of Hydroxyurea in an African Region With Malaria: Protocol for a Randomized Controlled Clinical Trial
por: Anyanwu, Juliana N, et al.
Publicado: (2016)

The influence of hydroxyurea on oxidative stress in sickle cell anemia
por: Torres, Lidiane de Souza, et al.
Publicado: (2012)

Platelet transfusions: trigger, dose, benefits, and risks
por: Blumberg, Neil, et al.
Publicado: (2010)

From Infancy to Adolescence: Fifteen Years of Continuous Treatment With Hydroxyurea in Sickle Cell Anemia
por: Hankins, Jane S., et al.
Publicado: (2014)

Risk factors for recurrent severe anemia among previously transfused children in Uganda: an age-matched case-control study
por: Dhabangi, Aggrey, et al.
Publicado: (2019)

5612617 EFFICACY AND SAFETY OF A SINGLE DOSE OF EXAGAMGLOGENE AUTOTEMCEL FOR TRANSFUSION-DEPENDENT-THALASSEMIA AND SEVERE SICKLE CELL DISEASE
por: de la Fuente, J., et al.
Publicado: (2023)

Efficacy of Hydroxyurea in Transfusion-Dependent Major β-Thalassemia Patients: A Meta-Analysis
por: Hatamleh, Modather I, et al.
Publicado: (2023)

Side effects of hydroxyurea in patients with Thalassemia major and thalassemia intermedia and sickle cell anemia
por: Ghasemi, A, et al.
Publicado: (2014)

Whole Exome Sequencing Identifies Novel Genes for Fetal Hemoglobin Response to Hydroxyurea in Children with Sickle Cell Anemia
por: Sheehan, Vivien A., et al.
Publicado: (2014)

Life-Threatening Acute Chest Syndrome in a Patient With Sickle Cell Disease After Switching From Hydroxyurea Therapy to Partial Exchange Transfusions: A Case Report
por: Kvam, Ann K, et al.
Publicado: (2021)

Comment on "The influence of hydroxyurea on oxidative stress in sickle cell anemia"
por: van Beers, Eduard Johannes, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_s59rtlu7n5qrrncftphokcv0sh